OBJECTIVE: Previous trials have demonstrated the efficacy and durability of computer-based cognitive-behavioral therapy (CBT4CBT) as an add-on to standard outpatient care in a range of treatment-seeking populations. In this study, the authors evaluated the efficacy and safety of CBT4CBT as a virtual stand-alone treatment, delivered with minimal clinical monitoring, and clinician-delivered cognitive-behavioral therapy (CBT) compared with treatment as usual in a heterogeneous sample of treatment-seeking outpatients with substance use disorders. METHOD: This was a randomized clinical trial in which 137 individuals who met DSM-IV-TR criteria for current substance abuse or dependence were randomly assigned to receive treatment as usual, weekly individual CBT, or CBT4CBT with brief weekly monitoring. RESULTS: Rates of treatment exposure differed by group, with the best retention in the CBT4CBT group and the poorest in the individual CBT group. Participants who received CBT or CBT4CBT reduced their frequency of substance use significantly more than those who received treatment as usual. Six-month follow-up outcomes indicated continuing benefit of CBT4CBT (plus monitoring) over treatment as usual, but not for clinician-delivered CBT over treatment as usual. Analysis of secondary outcomes indicated that participants in the CBT4CBT group demonstrated the best learning of cognitive and behavioral concepts, as well as the highest satisfaction with treatment. CONCLUSIONS: This first trial of computerized CBT as a virtual stand-alone intervention delivered in a clinical setting to a diverse sample of patients with current substance use disorders indicated that it was safe, effective, and durable relative to standard treatment approaches and was well-liked by participants. Clinician-delivered individual CBT, while efficacious within the treatment period, was unexpectedly associated with a higher dropout rate and lower effects at follow-up.
RCT Entities:
OBJECTIVE: Previous trials have demonstrated the efficacy and durability of computer-based cognitive-behavioral therapy (CBT4CBT) as an add-on to standard outpatient care in a range of treatment-seeking populations. In this study, the authors evaluated the efficacy and safety of CBT4CBT as a virtual stand-alone treatment, delivered with minimal clinical monitoring, and clinician-delivered cognitive-behavioral therapy (CBT) compared with treatment as usual in a heterogeneous sample of treatment-seeking outpatients with substance use disorders. METHOD: This was a randomized clinical trial in which 137 individuals who met DSM-IV-TR criteria for current substance abuse or dependence were randomly assigned to receive treatment as usual, weekly individual CBT, or CBT4CBT with brief weekly monitoring. RESULTS: Rates of treatment exposure differed by group, with the best retention in the CBT4CBT group and the poorest in the individual CBT group. Participants who received CBT or CBT4CBT reduced their frequency of substance use significantly more than those who received treatment as usual. Six-month follow-up outcomes indicated continuing benefit of CBT4CBT (plus monitoring) over treatment as usual, but not for clinician-delivered CBT over treatment as usual. Analysis of secondary outcomes indicated that participants in the CBT4CBT group demonstrated the best learning of cognitive and behavioral concepts, as well as the highest satisfaction with treatment. CONCLUSIONS: This first trial of computerized CBT as a virtual stand-alone intervention delivered in a clinical setting to a diverse sample of patients with current substance use disorders indicated that it was safe, effective, and durable relative to standard treatment approaches and was well-liked by participants. Clinician-delivered individual CBT, while efficacious within the treatment period, was unexpectedly associated with a higher dropout rate and lower effects at follow-up.
Authors: Kathleen M Carroll; Samuel A Ball; Steve Martino; Charla Nich; Theresa A Babuscio; Kathryn F Nuro; Melissa A Gordon; Galina A Portnoy; Bruce J Rounsaville Journal: Am J Psychiatry Date: 2008-05-01 Impact factor: 18.112
Authors: Brian D Kiluk; Kathleen M Carroll; Amy Duhig; Daniel E Falk; Kyle Kampman; Shengan Lai; Raye Z Litten; David J McCann; Ivan D Montoya; Kenzie L Preston; Phil Skolnick; Constance Weisner; George Woody; Redonna Chandler; Michael J Detke; Kelly Dunn; Robert H Dworkin; Joanne Fertig; Jennifer Gewandter; F Gerard Moeller; Tatiana Ramey; Megan Ryan; Kenneth Silverman; Eric C Strain Journal: Drug Alcohol Depend Date: 2015-11-21 Impact factor: 4.492
Authors: Kathleen M Carroll; Samuel A Ball; Steve Martino; Charla Nich; Theresa A Babuscio; Bruce J Rounsaville Journal: Drug Alcohol Depend Date: 2008-11-28 Impact factor: 4.492
Authors: Kathleen M Carroll; Lisa R Fenton; Samuel A Ball; Charla Nich; Tami L Frankforter; Julia Shi; Bruce J Rounsaville Journal: Arch Gen Psychiatry Date: 2004-03
Authors: Brian D Kiluk; Lara A Ray; Justin Walthers; Michael Bernstein; Jeffery S Tonigan; Molly Magill Journal: Alcohol Clin Exp Res Date: 2019-09-30 Impact factor: 3.455
Authors: Corey R Roos; Kathleen M Carroll; Charla Nich; Tami Frankforter; Brian D Kiluk Journal: Drug Alcohol Depend Date: 2020-05-12 Impact factor: 4.492
Authors: Marina C Fodor; Emily R Grekin; Jessica R Beatty; Lucy McGoron; Steven J Ondersma Journal: Subst Use Misuse Date: 2020-08-31 Impact factor: 2.164
Authors: Lisa A Marsch; Aimee Campbell; Cynthia Campbell; Ching-Hua Chen; Emre Ertin; Udi Ghitza; Chantal Lambert-Harris; Saeed Hassanpour; August F Holtyn; Yih-Ing Hser; Petra Jacobs; Jeffrey D Klausner; Shea Lemley; David Kotz; Andrea Meier; Bethany McLeman; Jennifer McNeely; Varun Mishra; Larissa Mooney; Edward Nunes; Chrysovalantis Stafylis; Catherine Stanger; Elizabeth Saunders; Geetha Subramaniam; Sean Young Journal: J Subst Abuse Treat Date: 2020-03
Authors: Manuel Paris; Michelle Silva; Luis Añez-Nava; Yudilyn Jaramillo; Brian D Kiluk; Melissa A Gordon; Charla Nich; Tami Frankforter; Kathleen Devore; Samuel A Ball; Kathleen M Carroll Journal: Am J Public Health Date: 2018-09-25 Impact factor: 9.308
Authors: Michelle A Silva; Yudilyn Jaramillo; Manuel Paris; Luis Añez-Nava; Tami L Frankforter; Brian D Kiluk Journal: J Subst Abuse Treat Date: 2019-12-13
Authors: Lara A Ray; Erica N Grodin; Lorenzo Leggio; Anita J Bechtholt; Howard Becker; Sarah W Feldstein Ewing; James David Jentsch; Andrea C King; Barbara J Mason; Stephanie O'Malley; James MacKillop; Markus Heilig; George F Koob Journal: Addict Biol Date: 2020-04-14 Impact factor: 4.280